Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., announced on April 10, 2025, a strategic partnership with Yuva Biosciences, Inc. The collaboration aims to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes, and other cardiometabolic conditions.
The partnership will leverage MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform. This platform will be used to compile a library of small molecule candidates that promote mitochondrial health and target the root cause of aging at the cellular level.
This collaboration represents a significant step in advancing AI-powered drug discovery for Northstrive Biosciences. The goal is to identify and develop new therapies that address critical unmet medical needs in metabolic health.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.